Form 4: Chimerix Director Vakiener Disposes of Stock Options Following Merger with Jazz Pharmaceuticals

Director Victoria Vakiener reports the disposal of Chimerix stock options following the company's merger with Jazz Pharmaceuticals on April 21, 2025.

Summary

• Victoria Vakiener, a director of Chimerix, filed a Form 4 detailing changes in beneficial ownership following the merger of Chimerix with Jazz Pharmaceuticals Public Limited Company.
• The merger was executed through a tender offer where Jazz Pharmaceuticals' subsidiary, Pinetree Acquisition Sub, Inc., acquired all outstanding shares of Chimerix for $8.55 per share in cash.
• The tender offer expired on April 17, 2025, and the merger was completed on April 21, 2025.
• As a result of the merger, Vakiener disposed of several employee stock options with various exercise prices and expiration dates.
• These options were 'in the money', meaning their exercise prices were less than the offer price of $8.55 per share.
• Vested 'in the money' options were cancelled and converted into the right to receive a cash payment equal to the difference between the offer price and the exercise price, multiplied by the number of shares subject to the option.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The merger provides a cash payout for option holders, which is generally viewed favorably. However, it also signifies the end of Chimerix as an independent entity.

Positives

• The merger provided a cash payment to option holders for 'in the money' options.

Negatives

• Director Vakiener no longer holds the disposed stock options.

Future Outlook

The document does not contain any specific forward-looking statements beyond the completion of the merger.

Industry Context

This announcement reflects a continuation of pharmaceutical industry consolidation, where larger companies acquire smaller entities to expand their product portfolios and pipelines. Jazz Pharmaceuticals' acquisition of Chimerix is consistent with this trend.

Comparison to Industry Standards

• Mergers and acquisitions are common in the pharmaceutical industry, with companies like Pfizer, Novartis, and Roche frequently engaging in similar transactions to acquire promising drug candidates or technologies.
• The $8.55 per share offer price represents a typical premium paid in such acquisitions, reflecting the value of Chimerix's assets and future potential.
• Comparable transactions often involve similar structures, including tender offers followed by a merger to ensure complete acquisition of the target company.

Stakeholder Impact

• Shareholders received $8.55 per share in cash.
• Option holders with 'in the money' options received a cash payment.
• Chimerix employees are now part of Jazz Pharmaceuticals.

Key Dates

Keywords

Merger, Chimerix, Jazz Pharmaceuticals, Stock Options, Form 4, Beneficial Ownership, Tender Offer, Director, Vakiener, CMRX